YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells

Molecular Pharmacology

Volumn 75, Issue 1, 2009, Pages 208-217

  Liu, Xiao Ming ^a   Peyton, Kelly J ^b   Mendelev, Natalia N ^c   Wang, Hong ^b   Tulis, David A ^c,d   Durante, William ^a,e  

^a University of Missouri   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^d EAST CAROLINA UNIVERSITY   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; 8 BROMO CYCLIC GMP; CARBON MONOXIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DT 2; GUANYLATE CYCLASE; HEME OXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOPROTEIN; KT 5720; KT 5823; LIGAND; MESSENGER RNA; NITRIC OXIDE; TYROSYLGLYCYLARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMINYLARGINYLARGINYLARGINYLPROLY LPROLYLLEUCYLARGINYLLYSYLLYSYLLYSYLLYSYLLYSYLHISTIDINAMIDE; UNCLASSIFIED DRUG; WORTMANNIN; 3-(5'-HYDROXYMETHYL-2'-FURYL)-1-BENZYLINDAZOLE; ENZYME ACTIVATOR; INDAZOLE DERIVATIVE;

ALLOSTERISM; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; GENE AMPLIFICATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; RAT; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; CELLS, CULTURED; ENZYME ACTIVATORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEME OXYGENASE (DECYCLIZING); INDAZOLES; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE TYPE II; RATS; RNA, MESSENGER;

EID: 58849157968     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.048314     Document Type: Article

References (40)

1. Alam J and Cook JL (2007) How many transcription factors does it take to turn on the heme oxygenase-1 gene? Am J Respir Cell Mol Biol 36:166-174.
2. Boese M, Busse R, Mülsch A, and Schini-Kerth V (1996) Effect of cyclic GMP-dependent vasodilators on the expression of inducible nitric oxide synthase in vascular smooth muscle cells: role of cyclic AMP. Br J Pharmacol 119:707-715.
3. Burkhardt M, Glazova M, Gambaryan S, Vollkommer T, Butt E, Bader B, Heermeier K, Lincoln TM, Walter U, and Palmetshofer A (2000) KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in intact human platelets and rat mesangial cells. J Biol Chem 275:33536-33541.
4. Cornwell TL, Arnold E, Boerth NJ, and Lincoln TM (1994) Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 267:C1405-C1413.
5. Durante W, Johnson FK, and Johnson RA (2006) Role of carbon monoxide in cardiovascular function. J Cell Mol Med 10:672-686.
6. Durante W, Schini VB, Catovsky S, Kroll MH, Vanhoutte PM, and Schafer AI (1993) Plasmin potentiates induction of nitric oxide synthase in vascular smooth muscle cells. Am J Physiol 264:H617-H624.
7. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, and Stasch JP (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5:755-768.
8. Friebe A and Koesling D (1998) Mechanism of YC-1-induced activation of soluble guanylate cyclase. Mol Pharmacol 53:123-127.
9. Friebe A, Schultz G, and Koesling D (1996) Sensitizing soluble guanylate cyclase to become a highly CO-sensitive enzyme. EMBO J 15:6863-6868.
10. Hsiao G, Huang HY, Fong TH, Shen MY, Lin CH, Teng CM, and Sheu JR (2004) Inhibitory mechanisms of YC-1 and PMC in the induction of iNOS expression by lipoteichoic acid in RAW 264.7 macrophages. Biochem Pharmacol 67:1411-1419.
11. Hwang TL, Hung HW, Kao SH, Teng CM, Wu CC, and Cheng SJ (2003) Soluble guanylate cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway. Mol Pharmacol 64:1419 -1427.
12. Iimura O, Kusano E, Homma S, Takeda S, Ikeda U, Shimada K, and Asano Y (1998) Atrial natriuretic peptide enhances IL-1β-stimulated nitric oxide production in cultured rat vascular smooth muscle cells. Kidney Blood Press Res 21:36-41.
13. Kibbe M, Billiar T, and Tzeng E (1999) Inducible nitric oxide synthase and vascular injury. Cardiovasc Res 43:650-657.
14. Ko FN, Wu CC, Kuo SC, Lee FY, and Teng CM (1994) YC-1, a novel activator of platelet guanylate cyclase. Blood 84:4226-4233.
15. Lee TS, Chang CC, Zhu Y, and Shyy JY (2004) Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 110:1296 -1302.
16. Lee YC, Martin E, and Murad F (2000) Human recombinant soluble guanylate cyclase: expression, purification, and regulation. Proc Natl Acad Sci U S A 97:10763-10768.
17. Liu XM, Peyton KJ, Ensenat D, Wang H, Hannink M, Alam J, and Durante W (2007) Nitric oxide stimulates heme oxygenase-1 gene transcription via the Nrf2/ARE complex to promote vascular smooth muscle cell survival. Cardiovasc Res 75:381-389.
18. Liu YN, Pan SL, Peng CY, Guh JH, Huang DM, Chang YL, Lin CH, Pai HC, Kuo SC, Lee FY, et al. (2006) YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1- benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions of activities of matrix metalloproteinases 2 and 9. J Pharmacol Exp Ther 316:35-41.
19. Lu DY, Tang CH, Liou HC, Teng CM, Jeng KC, Kuo SC, Lee FY, and Fu WM (2007) YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-κB. Br J Pharmacol 151:396-405.
20. Marshall HE and Stamler JS (2001) Inhibition of NF-κB by S-nitrosylation. Biochemistry 40:1688-1693.
21. McLaughlin BE, Chretien ML, Choi C, Brien JF, Nakatsu K, and Marks GS (2000) Potentiation of carbon monoxide-induced relaxation of rat aorta by YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole]. Can J Physiol Pharmacol 78:343-349.
22. Motterlini R, Sawle P, Hammad J, Bains S, Alberto R, Foresti R, and Green CJ (2005) CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule. FASEB J 19:284-286.
23. Mülsch A, Bauersachs J, Schäfer A, Stasch JP, Kast R, and Busse R (1997) Effect of YC-1, an NO-independent, superoxide sensitive stimulator of soluble guanylate cyclase, on smooth muscle cell responsiveness to nitrovasodilators. Br J Pharmacol 120:681-689.
24. Pan SL, Guh JH, Chang YL, Kuo SC, Lee FY, and Teng CM (2004) YC-1 prevents sodium nitroprusside-mediated apoptosis in vascular smooth muscle cells. Cardiovasc Res 61:152-158.
25. Pan SL, Guh JH, Peng CY, Chang YL, Cheng FC, Chang JH, Kuo SC, Lee FY, and Teng CM (2005) A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. Thromb Haemost 93:940-948.
26. Pugazhenthi S, Akhov L, Selvaraj G, Wang M, and Alam J (2007) Regulation of heme oxygenase-1 expression by demethoxy curcuminoids through Nrf2 by PI3-kinase/Akt mediated pathway in mouse beta-cells. Am J Physiol Endocrinol Metab 293:E645-E655.
27. Reynaert NL, Ckless K, Korn SH, Vos N, Guala AS, Wouters EF, van der Vliet A, and Janssen-Heininger YM (2004) Nitric oxide represses inhibitory κB kinase through S-nitrosylation. Proc Natl Acad Sci U S A 101:8945-8950.
28. Rothermund L, Friebe A, Paul M, Koesling D, and Kreutz R (2000) Acute blood pressure effects of YC-1-induced activation of soluble guanylate cyclase in normotensive and hypertensive rats. Br J Pharmacol 130:205-208.
29. Russwurm M, Mergia E, Mullershausen F, and Koesling D (2002) Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J Biol Chem 277:24883-24888.
30. Schmidt K, Schrammel A, Koesling D, and Mayer B (2001) Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells. Mol Pharmacol 59:220-224.
31. Sikorski EM, Hock T, Hill-Kapturczak N, and Agarwal A (2004) The story so far: molecular regulation of the heme oxygenase-1 gene in renal injury. Am J Physiol Renal Physiol 286:F425-F441.
32. Stone JR and Marletta MA (1998) Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the ironhistidine bond during activation by nitric oxide. Chem Biol 5:255-261.
33. Teng CM, Wu CC, Ko FN, Lee FY, and Kuo SC (1997) YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 320:161-166.
34. Tulis DA (2004) Salutary properties of YC-1 in the cardiovascular and hematological systems. Curr Med Chem Cardiovasc Hematol Agents 2:343-359.
35. Tulis DA, Bohl Masters KS, Lipke EA, Schiesser RL, Evans AJ, Peyton KJ, Durante W, West JL, and Schafer AI (2002) YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem Biophys Res Commun 291:1014-1021.
36. Tulis DA, Durante W, Peyton KJ, Chapman GB, Evans AJ, and Schafer AI (2000) YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem Biophys Res Commun 279:646-652.
37. Wang JP, Chang LC, Raung SL, Hsu MF, Huang LJ, and Kuo SC (2002) Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cGMP-dependent and -independent mechanisms. Biochem Pharmacol 63:577-585.
38. Wohlfart P, Malinski T, Ruetten H, Schindler U, Linz W, Schoenafinger K, Strobel H, and Wiemer G (1999) Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylate cyclase. Br J Pharmacol 128:1316-1322.
39. Wu CH, Chang WC, Chang GY, Kuo SC, and Teng CM (2004) The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study. J Pharmacol Sci 94:252-260.
40. Wu L and Wang R (2005) Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev 57:585-630.